Abstract. The purpose of the present study was to assess the prognostic impact of T-cadherin expression in patients with triple-negative breast cancer (TNBC). On the basis of the results of immunohistochemical analysis, 106 patients with operable TNBC were divided into two groups, the T-cadherin-positive group and T-cadherin-negative group. Fisher's exact and χ
Introduction
In recent years, the development of comprehensive therapy (surgical resection combined with chemo-, immuno-or radiotherapy) (1) has reduced the mortality rate of patients with breast cancer (2, 3) . However, the mortality of patients with triple-negative breast cancer (TNBC) remains high (4) (5) (6) . TNBC is a specific subtype of breast cancer that is distinguished by a lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression (7, 8) . TNBC is characterized by aggressive clinical behavior, including early distant metastasis, recurrence, a lack of specific therapeutic targets and poorer prognosis than other subtypes of breast cancer (9) (10) (11) . Chemotherapy is the primary systemic therapeutic approach for TNBC treatment, although only ~20% of patients with TNBC are sensitive to chemotherapy (12) . To improve the prognosis of TNBC, the molecular and biological mechanisms that underlie its aggressive behavior require clarification. The emergence of novel markers for an effective targeted therapy could change the current TNBC treatment strategies.
The cadherins are a family of cell-surface glycoproteins responsible for mediating calcium-dependent homophilic intercellular adhesion. The adhesive properties of classical cadherin adhesion molecules serve an essential role in the maintenance of tissue (13) (14) (15) (16) . T-cadherin is an atypical cadherin lacking in the transmembrane and cytoplasmic domains and is linked to the plasma membrane by the glycosylphosphatidylinositol (GPI) anchor (17) (18) (19) .
T-cadherin expression has been considered to be a useful tool to stratify tumors and identify the degree of T-cadherin involvement in specific steps of cancer progression (20, 21) . Downregulation of T-cadherin is frequently observed in multiple types of cancer, including ovarian carcinoma (22) , gastric cancer (23), colorectal cancer (24), hepatocellular carcinoma (25) , bladder transitional cell carcinoma (26) , breast cancer (27) and gallbladder cancer (19) , and is generally associated with poor patient outcome.
Previous studies have revealed that the process of tumor cell development and invasion, induced by the epidermal growth factor, may be inhibited by the high expression of T-cadherin (28) (29) (30) progression and may therefore represent a potential biomarker for certain types of cancer. T-cadherin downregulation has been observed in malignant breast tumors (31) and is often methylated in primary and metastatic tumor tissues of patients with breast cancer (32). Toyooka et al (33) revealed that T-cadherin may function as a tumor suppressor gene in breast cancer. Taken together, these findings indicate that T-cadherin may serve as a prognostic marker for breast cancer development (31) (32) (33) . Breast cancer is usually classified into biologically distinct, behaviorally different subtypes by the presence of immunohistochemically detected markers (34) ; however, the immunohistological determination of T-cadherin expression in breast cancer is rarely reported.
Previous studies revealed that a lack of T-cadherin expression was significantly associated with poorer prognosis of patients with axillary lymph node-positive breast cancer; a multivariate analysis demonstrated that T-cadherin expression was an independent prognostic factor for disease-free survival (DFS) (P=0.002), but not for overall survival (OS) (P=0.067) (35) , indicating that there may be an association between the expression of T-cadherin and the prognosis of patients with axillary lymph node-positive breast cancer. To date, the role served by T-cadherin in the prognosis and metastasis of TNBC remains unclear.
In the present study, immunohistochemistry was used to determine the T-cadherin expression in 106 formalin-fixed TNBC specimens. The current study aimed to assess the clinicopathological significance of T-cadherin expression, and examine whether T-cadherin expression was an independent predictor of survival of the patients with TNBC.
Materials and methods

Subjects.
A total of 106 females with TNBC who were enrolled in the Jining No. 1 People's Hospital (Jining, China) between January 2003 and December 2009 were randomly chosen for the present study (age range, 22-75 years; mean age, 49.6 years). Patients with invasive breast carcinoma were enrolled; patients with invasive lobular carcinoma were excluded. All patients underwent chemotherapy or chemotherapy in combination with radiotherapy, as detailed in Table I . All patients provided written informed consent.
All tissues were immediately fixed in 10% formalin for 24 h and embedded in paraffin. The clinicopathological features were collected retrospectively and analyzed. According to the results of pathological immunohistochemistry, the 106 patients were divided into two groups, T-cadherin-negative and T-cadherin-positive. The present study was approved by the Ethics Committee of Jining No. 1 People's Hospital (Jining, China). No significant differences were identified in the clinicopathological information between the two groups. Demographic data of the patients are listed in Table I .
Immunohistochemical (IHC) staining. Staining was performed as described previously (35) . The following reagents were used for the IHC assay and all purchased from Fuzhou Maixin Biotechnology Development Co. Ltd. (Fuzhou, China): 3,3'-diaminobenzidine (DAB) color liquid, mouse anti-human T-cadherin monoclonal antibody (catalog no. H00001012-M01A; dilution, 1:100), Tris-buffered saline, an UltraSensitive™ SP (mouse) IHC kit (KIT-9702) and PBS. The immunoreactive products were visualized using a light microscope by the catalysis of DAB using horseradish peroxidase in the presence of H 2 O 2 following extensive washing (magnification, x200). A total of 22 fields of view were assessed and images were captured using a DP25 camera (Olympus Corporation, Tokyo, Japan).
Positive staining of T-cadherin was primarily observed at the cell membrane. For semi-quantitative analysis, the positive cell staining intensity and percentage of cells stained per slide were scored. The results of staining were (-), (+), (++), and (+++) according to T-cadherin expression level. (-) and (+) indicated that T-cadherin expression was negative, while (++) and (+++) indicated that T-cadherin expression was positive (36) . Staining intensity was determined as follows: 0, no color; 1, light yellow; 2, brown; 3, tan. The percentage of positively stained cells was defined as: 0, ≤20%; 1, 21-50%; 2, 51-75%; 3, >75%. The final scores were calculated by considering the percentage of positively stained cells and staining intensity results, as previously described (37): negative (-), 0; weak positive (+), 1-3; medium positive (++), 4-6; strong positive (+++), 7-9. The immunohistochemical assessment was performed independently by two experienced pathological physicians.
Determination of ER/PR/HER-2.
The presence of HER-2 was determined using a HercepTest kit (DakoCytomation, Carpinteria, CA, USA) according to manufacturer's protocol. The presence of PR and ER was determined immunohistochemically, using a monoclonal antibody targeted at PR (clone 16; cat no. ORG-8721; pre-diluted) and a monoclonal antibody targeted at ER (clone 611; cat no. ORG-8871; pre-diluted) (both from Leica Microsystems, Inc., Buffalo Grove, IL, USA), according to previously published procedures (38) .
Follow up. Patients were followed up for 5 years. The 5-year DFS was used to determine the primary endpoint and 5-year OS was used to determine the secondary endpoint. DFS referred to the interval from the time of surgery to the time of such events as local relapse, distant metastasis, death from any cause, or the last follow-up. The interval from the time of surgery to the time of death or the last follow-up was used to define OS.
Statistical analysis. All data were analyzed using SPSS statistical software (version 17.0; SPSS, Inc., Chicago, IL, USA). Besides T-cadherin expression, the following clinicopathological parameters were analyzed: Family history, age, menopausal status, lymph node status, lymph-vascular invasion, tumor size, histological grade [Elston-Ellis modification of Bloom-Richardson grading system; Bloom-Richardson-Elston (BRE) score] (39), pathological status and histological disease type (36) . A χ 2 test was employed to analyze the association between T-cadherin expression and the clinicopathological parameters. Survival curves based on T-cadherin expression were estimated using the Kaplan-Meier product-limit method, and the log-rank test was used to determine the influence of the T-cadherin expression on 5-year DFS and OS. Kaplan-Meier function and Cox regression analyses were used to analyze DFS and OS. P<0.05 was considered to indicate a statistically significant difference.
Results
T-cadherin expression is associated with clinicopathological parameters.
Of the 106 patients with TNBC, T-cadherin-negative patients accounted for 66.04% (70/106), and T-cadherin-positive patients accounted for 33.96% (36/106). T-cadherin protein was expressed at the cell membrane (Fig. 1) according to the results of immunohistochemical analysis. No significant differences were identified between the two groups in terms of family history, age, lymph-vascular invasion, pathological stage [tumor-node-metastasis (TNM) staging was assessed according to the staging system established by the American Joint Committee on Cancer] (40), histological types or menopausal status (P>0.05; Table I ). However, tumor size >2 cm, BRE grade II and III, and positive lymph node status were more common in the negative group compared with the Table I . Association between T-cadherin expression and clinicopathological parameters in 106 patients with triple-negative breast cancer.
Parameters
T-cadherin-negative, n (%) T-cadherin-positive, n (%) . The influence of the T-cadherin expression on 5-year DFS and 5-year OS was determined using the log-rank test.
The 5-year DFS and 5-year OS of the T-cadherin-negative group were lower compared with those of the T-cadherin-positive group (Z=6.233, P=0.013; Z=5.366, P=0.021) (Fig. 2) . In terms of univariate survival analysis (Table II) , there were shorter DFS (P=0.014) and OS (P=0.022) for T-cadherin-negative patients compared with T-cadherin-positive patients. Lymph-vascular invasion was associated with a significantly shorter DFS (P= 0.001) and OS (P= 0.014), and positive lymph node status was associated with a significantly shorter DFS (P=0.008) and OS (P=0.024). TNM staging III was associated with a significantly shorter DFS only (P=0.029) (Table II) . Table III . Multivariate analyses of disease-free survival of 106 patients with triple-negative breast cancer. In terms of multivariate Cox regression analysis, lymph-vascular invasion and tumor size >2 cm (Wald =15.148 and Wald =4.255, respectively; P<0.001 and P=0.039, respectively) were other factors that reached significance for predicting DFS (Table III) . Lymph-vascular invasion was a factor that reached significance for predicting OS (Wald =5.081; P=0.024; Table IV) . Furthermore, T-cadherin expression was an independent prognostic factor for DFS (Wald =6.758; P=0.009; Table III ) and OS (Wald =3.910; P=0.048; Table IV) .
95.0% CI for RR ---------------------------------------------
Discussion
According to the current study, patients with negative T-cadherin expression were associated with more aggressive TNBC clinicopathological features. The DFS and OS of the patients with T-cadherin-negative expression were decreased.
To the best of our knowledge, the present study is the first to perform immunohistochemical analysis on T-cadherin expression in TNBC. A significant association was identified between negative T-cadherin expression and a tumor size >2 cm, histological grade II and III, and positive lymph node status in TNBC (P<0.05). Negative T-cadherin expression was significantly associated with poor TNBC patient prognosis. Multivariate analysis revealed that T-cadherin expression was an independent prognostic factor for DFS (P=0.009) and OS (P=0.048).
There are several limitations to the present study. First, the sample size was small, which reduced the power of the study, and a number of patients were lost in follow-up, reducing the power further. Second, patients with invasive lobular carcinoma were excluded, thus whether invasive lobular carcinoma had altered T-cadherin expression remains unknown. Third, data at the molecular/genetic level were not provided. It is hoped that a large-sample multi-center study will be performed in the future, verifying the findings of the present study.
According to the results of the current study, T-cadherin expression was associated with the clinicopathological features and prognosis of TNBC. For patients with TNBC, T-cadherin-negative expression was a prognostic factor, and T-cadherin may serve as a marker of TNBC, contributing to more precise prediction of prognosis. Table IV . Multivariate analyses on overall survival of 106 patients with triple-negative breast cancer. 
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